TM
RXRX icon

Torren Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Torren Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-986
Closed -$4.03K – 1371
2025
Q4 		$4.03K Buy
+986
New +$4.88K ﹤0.01% 950

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Torren Management's RXRX Position: Q1 2026 in Review

Torren Management sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 986 shares — an estimated $4.03K sold.

Torren Management first reported a position in RXRX in Q4 2025 and held it in 1 quarter. The position peaked at $4.03K in Q4 2025. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Torren Management reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Torren Management sold 986 Recursion Pharmaceuticals shares in Q1 2026, an estimated $4.03K.
  • Torren Management first reported a position in Recursion Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Torren Management's Recursion Pharmaceuticals position peaked at $4.03K in Q4 2025.
  • 335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.